GE HealthCare Technologies Inc. (GEHC)
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
- Symbol
- GEHC
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Medical Devices
- Market cap
- $30.14B
- 52 week range
- 58.75 - 89.77
Valuation
- Share price
- $66.09 (close of 2026-09-23)
- P/E (TTM)
- 15.81x
- Price to book
- 2.82x
- Price to free cash flow
- 19.84x
- Enterprise value
- $38.45B
- Book value per share
- $23.42
Price performance
| Period | Change |
|---|
| 1 day | +1.98% |
| 5 days | +3.15% |
| 1 month | -11.67% |
| 3 months | +3.72% |
| 6 months | -7.76% |
| Year to date | -19.42% |
| 1 year | -11.41% |
| 3 years | +3.45% |
| All time | +10.15% |
Profitability and growth
- Return on equity
- 20.06%
- Return on invested capital
- 13.13%
- Return on assets
- 5.65%
- Return on capital employed
- 9.94%
- Gross margin
- 39.99%
- Net margin
- 10.10%
- EBITDA margin
- 14.79%
- Revenue growth
- 4.84%
- Net income growth
- 4.57%
- Free cash flow growth
- -3.15%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 5.04%
- Current ratio
- 1.22x
- Net debt to EBITDA
- 2.31x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $20.63B
- Cost of revenue
- $12.38B
- Gross profit
- $8.25B
- EBITDA
- $3.05B
- Net income
- $2.08B
- Earnings per share
- $4.56
- Research and development
- $1.26B
- Interest expense
- $440.00M
- Shares outstanding
- 456.00M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $20.63B | $8.25B | $2.08B | $4.56 |
| 2024-12-31 | $19.67B | $8.21B | $1.99B | $4.37 |
| 2023-12-31 | $19.55B | $7.92B | $1.57B | $3.05 |
| 2022-12-31 | $18.34B | $7.18B | $1.92B | $4.22 |
| 2021-12-31 | $17.59B | $7.17B | $2.25B | $4.95 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 39.99% | 10.10% | 20.06% | 13.13% |
| 2024-12-31 | 41.71% | 10.13% | 23.55% | 13.99% |
| 2023-12-31 | 40.52% | 8.02% | 21.95% | 11.66% |
| 2022-12-31 | 39.14% | 10.45% | 20.47% | 11.83% |
| 2021-12-31 | 40.80% | 12.78% | 13.47% | 13.62% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $4.49B | $9.49B |
| 2024-12-31 | $2.87B | $7.45B |
| 2023-12-31 | $2.49B | $8.44B |
| 2022-12-31 | $1.44B | $8.23B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $1.50B | $130.00M |
| 2024-12-31 | $1.55B | $125.00M |
| 2023-12-31 | $1.71B | $114.00M |
| 2022-12-31 | $1.82B | $67.00M |
| 2021-12-31 | $1.36B | $76.00M |
Dividend history
- Most recent payment
- 2026-07-24
- Paid in the last twelve months
- $0.14
| Payment date | Dividend per share |
|---|
| 2026-07-24 | $0.04 |
| 2026-04-02 | $0.04 |
| 2026-01-09 | $0.04 |
| 2025-10-24 | $0.04 |
| 2025-07-25 | $0.04 |
| 2025-04-25 | $0.04 |
| 2025-01-14 | $0.04 |
| 2024-10-18 | $0.03 |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
- Consensus EPS estimate
- $1.21
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-29 | Jun/2026 | $1.04 |
| 2026-04-29 | - | - |
| 2026-02-04 | - | - |
| 2025-10-29 | - | - |
| 2025-07-30 | - | - |
| 2025-04-30 | - | - |
| 2025-02-13 | - | - |
| 2024-10-30 | - | - |
Filings and sources
- Company website
- gehealthcare.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Abbott Laboratories (ABT) · Medtronic plc (MDT) · Stryker Corp (SYK) · Boston Scientific Corp (BSX) · Edwards Lifesciences Corp (EW) · Dexcom Inc (DXCM) · STERIS plc (STE) · Zimmer Biomet Holdings, Inc. (ZBH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades